Neumora Therapeutics (NMRA) Profit After Tax (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Profit After Tax of -$53.5 million for Q1 2026, up 21.45% year-over-year from -$44.0 million in Q1 2025, and up 10.09% quarter-over-quarter from -$59.5 million in Q4 2025.
Neumora Therapeutics (NMRA) Profit After Tax (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Profit After Tax history runs 5 years deep, the most recent figure standing at -$53.5 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 21.45% year-over-year to -$53.5 million; the TTM figure through Mar 2026 stood at -$222.4 million (up 13.79% YoY), while the FY2025 annual figure was -$237.0 million, up 2.73% from the prior year.
- Profit After Tax for Q1 2026 stood at -$53.5 million, up from -$59.5 million in the prior quarter.
- The five-year high for Profit After Tax was -$28.9 million in Q4 2022, with the low at -$109.2 million in Q4 2023.
- The 5-year median for Profit After Tax is -$53.7 million (2024), against an average of -$55.3 million.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax slumped 277.57% in 2023, then jumped 46.26% in 2024.
- Neumora Therapeutics' Profit After Tax stood at -$28.9 million in 2022, then plunged by 277.57% to -$109.2 million in 2023, then surged by 46.26% to -$58.7 million in 2024, then decreased by 1.33% to -$59.5 million in 2025, then rose by 10.09% to -$53.5 million in 2026.
- Business Quant data shows NMRA's Profit After Tax at -$53.5 million in Q1 2026, -$59.5 million in Q4 2025, and -$56.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | -53.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.46 Mn |
| Dec 31, 2025 | -59.46 Mn |
| Sep 30, 2025 | -56.76 Mn |
| Jun 30, 2025 | -52.73 Mn |
| Mar 31, 2025 | -68.06 Mn |
| Dec 31, 2024 | -58.68 Mn |
| Sep 30, 2024 | -72.55 Mn |
| Jun 30, 2024 | -58.70 Mn |
| Mar 31, 2024 | -53.72 Mn |
| Dec 31, 2023 | -109.19 Mn |
| Sep 30, 2023 | -53.03 Mn |
| Jun 30, 2023 | -38.54 Mn |
| Mar 31, 2023 | -35.63 Mn |
| Dec 31, 2022 | -28.92 Mn |
| Sep 30, 2022 | -29.63 Mn |